Literature DB >> 28148584

Psoriatic arthritis: state of the art review.

Laura C Coates1, Philip S Helliwell2.   

Abstract

Psoriatic arthritis (PsA) accounts for around 20% of referrals to the early arthritis clinic and presents a significant diagnostic and management challenge. Early diagnosis is important to prevent long term functional disability and to ensure optimal management of arthritis and key comorbidities. From the rheumatologist's perspective, the differential diagnosis includes rheumatoid arthritis, gout and other inflammatory arthritides. Once diagnosed, it is essential to assess the disease fully, including arthritis, enthesitis, dactylitis, skin/nail disease and axial involvement. Using this information, appropriate treatment can be planned using therapies that are effective at treating the relevant domains of disease. Despite poor data, traditional disease-modifying anti-rheumatic drugs are commonly used and have been effective in observational studies. Following tumour necrosis factor inhibitors, which have proven excellent efficacy in multiple domains of PsA, new biologics are available or in development and will improve treatment options for people with refractory PsA. © Royal College of Physicians 2017. All rights reserved.

Entities:  

Keywords:  Assessment; diagnosis; psoriatic arthritis; treatment

Mesh:

Year:  2017        PMID: 28148584      PMCID: PMC6297592          DOI: 10.7861/clinmedicine.17-1-65

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


  37 in total

1.  Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).

Authors:  Christian E Antoni; Arthur Kavanaugh; Bruce Kirkham; Zuhre Tutuncu; Gerd R Burmester; Udo Schneider; Daniel E Furst; Jerry Molitor; Edward Keystone; Dafna Gladman; Bernhard Manger; Siegfried Wassenberg; Ralf Weier; Daniel J Wallace; Michael H Weisman; Joachim R Kalden; Josef Smolen
Journal:  Arthritis Rheum       Date:  2005-04

2.  Classification criteria for psoriatic arthritis: development of new criteria from a large international study.

Authors:  William Taylor; Dafna Gladman; Philip Helliwell; Antonio Marchesoni; Philip Mease; Herman Mielants
Journal:  Arthritis Rheum       Date:  2006-08

3.  Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.

Authors:  Philip J Mease; Dafna D Gladman; Christopher T Ritchlin; Eric M Ruderman; Serge D Steinfeld; Ernest H S Choy; John T Sharp; Peter A Ory; Renee J Perdok; Mark A Weinberg
Journal:  Arthritis Rheum       Date:  2005-10

Review 4.  Interventions for psoriatic arthritis.

Authors:  G Jones; M Crotty; P Brooks
Journal:  Cochrane Database Syst Rev       Date:  2000

5.  Risk of myocardial infarction in patients with psoriasis.

Authors:  Joel M Gelfand; Andrea L Neimann; Daniel B Shin; Xingmei Wang; David J Margolis; Andrea B Troxel
Journal:  JAMA       Date:  2006-10-11       Impact factor: 56.272

6.  Comparison of disability and quality of life in rheumatoid and psoriatic arthritis.

Authors:  K B Sokoll; P S Helliwell
Journal:  J Rheumatol       Date:  2001-08       Impact factor: 4.666

7.  Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.

Authors:  C Antoni; G G Krueger; K de Vlam; C Birbara; A Beutler; C Guzzo; B Zhou; L T Dooley; A Kavanaugh
Journal:  Ann Rheum Dis       Date:  2005-01-27       Impact factor: 19.103

8.  Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression.

Authors:  Philip J Mease; Alan J Kivitz; Francis X Burch; Evan L Siegel; Stanley B Cohen; Peter Ory; David Salonen; Joel Rubenstein; John T Sharp; Wayne Tsuji
Journal:  Arthritis Rheum       Date:  2004-07

9.  Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial.

Authors:  J Peter Kaltwasser; Peter Nash; Dafna Gladman; Cheryl F Rosen; Frank Behrens; Peter Jones; Jürgen Wollenhaupt; Franziska G Falk; Philip Mease
Journal:  Arthritis Rheum       Date:  2004-06

10.  Predictors for radiological damage in psoriatic arthritis: results from a single centre.

Authors:  Simon J Bond; Vernon T Farewell; Catherine T Schentag; Dafna D Gladman
Journal:  Ann Rheum Dis       Date:  2006-08-17       Impact factor: 19.103

View more
  47 in total

Review 1.  Clinical Features of Psoriatic Arthritis: a Comprehensive Review of Unmet Clinical Needs.

Authors:  Angela McArdle; Stephen Pennington; Oliver FitzGerald
Journal:  Clin Rev Allergy Immunol       Date:  2018-12       Impact factor: 8.667

2.  Early arthritis clinic is effective for rheumatoid and psoriatic arthritides.

Authors:  M K Nisar
Journal:  Rheumatol Int       Date:  2019-02-19       Impact factor: 2.631

Review 3.  Metabolic Profiling in Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis: Elucidating Pathogenesis, Improving Diagnosis, and Monitoring Disease Activity.

Authors:  Erika Dorochow; Michaela Köhm; Lisa Hahnefeld; Robert Gurke
Journal:  J Pers Med       Date:  2022-06-02

4.  Association between uveitis and psoriatic disease: a systematic review and Meta-analysis based on the evidence from cohort studies.

Authors:  Chao-Ran Li; Lang Chen; Long-Fei Wang; Bin Yan; You-Ling Liang; Jing Luo
Journal:  Int J Ophthalmol       Date:  2020-04-18       Impact factor: 1.779

5.  Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE).

Authors:  Florenzo Iannone; Leonardo Santo; Romano Bucci; Angelo Semeraro; Giorgio Carlino; Franco Paoletti; Laura Quarta; Pierfrancesco Leucci; Carmelo Zuccaro; Antonio Marsico; Crescenzio Scioscia; Francesca D'Onofrio; Daniela Mazzotta; Maurizio Muratore; Francesco Paolo Cantatore; Giovanni Lapadula
Journal:  Clin Rheumatol       Date:  2018-02-07       Impact factor: 2.980

6.  Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis.

Authors:  Philip J Mease; Iain B McInnes; Lai-Shan Tam; Kiefer Eaton; Steve Peterson; Agata Schubert; Soumya D Chakravarty; Anna Parackal; Chetan S Karyekar; Sandhya Nair; Wolf-Henning Boehncke; Christopher Ritchlin
Journal:  Rheumatology (Oxford)       Date:  2021-05-14       Impact factor: 7.580

7.  Diagnostic Delay in Psoriatic Arthritis: A Population-based Study.

Authors:  Paras Karmacharya; Kerry Wright; Sara J Achenbach; Delamo Bekele; Cynthia S Crowson; Alexis Ogdie; Alí Duarte-García; Floranne C Ernste; Megha M Tollefson; John M Davis
Journal:  J Rheumatol       Date:  2021-02-15       Impact factor: 5.346

Review 8.  Residual Disease Associated with Suboptimal Treatment Response in Patients with Psoriatic Arthritis: A Systematic Review of Real-World Evidence.

Authors:  Laura C Coates; Maarten de Wit; Amy Buchanan-Hughes; Maartje Smulders; Anna Sheahan; Alexis R Ogdie
Journal:  Rheumatol Ther       Date:  2022-04-12

Review 9.  Axial Psoriatic Disease: Clinical and Imaging Assessment of an Underdiagnosed Condition.

Authors:  Ivan Giovannini; Alen Zabotti; Carmelo Cicciò; Matteo Salgarello; Lorenzo Cereser; Salvatore De Vita; Ilaria Tinazzi
Journal:  J Clin Med       Date:  2021-06-27       Impact factor: 4.241

10.  Medication adherence and persistence of psoriatic arthritis patients treated with biological therapy in a specialty pharmacy in Brazil: a prospective observational study.

Authors:  Ana F Souza; Michael R Da Silva; Jéssica B Dos Santos; Alessandra M Almeida; Francisco A Acurcio; Juliana Alvares-Teodoro
Journal:  Pharm Pract (Granada)       Date:  2021-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.